Can-Fite Reports Third Quarter 2022 Financial Results & Provides Clinical Update - Can Fite Biofarma (AME
Can-Fite BioPharma Ltd. CANF CFBI, a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced financial results for the quarter ended September 30, 2022.
Corporate and Clinical Development Highlights Include:
Complete Clearance of Cancer in a Patient Treated with Namodenoson was Presented at the AASLD Liver Meeting A poster titled Complete Response Induced by Namodenoson, an A3 Adenosine Receptor Agonist, in a Patient with Advanced Hepatocellular Carcinoma was presented at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in November in Washington, D.C. The findings were published in the October 2022 supplement of HEPATOLOGY, a premier peer-reviewed journal in the field of liver disease. The poster detailed the patient, a 61-year-old woman with hepatocellular carcinoma (HCC), the most common form of liver cancer, and moderate hepatic dysfunction Child-Pugh B (CPB7), who participated in Can-Fite's prior Phase II study. The patient was in the Namodenoson arm of the Phase II study and continued treatment with Namodenoson for 5 years under an open label extension program until the approval of a compassionate use program in Romania in August.
Continue read on benzinga.com